Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib
Conclusions:
The 8-week tumor volume decrease of>74% is significantly associated with longer OS in patients with ALK-rearranged NSCLC treated with crizotinib.
Source: Journal of Thoracic Imaging - Category: Radiology Tags: Original Articles Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Radiology | Women